Fig 4. Budesonide treatment does not attenuate neutrophils and reduces IL-6 and interferon levels.

C57B/6 mice were given vehicle or 350–700 μg/kg budesonide oropharyngeally (o.p.) on days -2-2, and 10 μg polyI:C o.p. on days 0–2. On day 3, 0.2 mg 4kDa FITC-dextran was instilled o.p. and 1 hr later BALF was harvested. A-C) CXCL1, IFN-lambda and IL-6 levels were quantified via ELISA, and D) neutrophils were assessed via cytospin and hematoxylin and eosin staining. Data are mean ± standard deviation. One way ANOVA followed by unpaired Tukey’s multiple comparisons test. *p<0.05, ** p< 0.01; ***p<0.001; **** p<0.0001.